Product nameAnti-ARSB antibody [EPR9409]
See all ARSB primary antibodies
DescriptionRabbit monoclonal [EPR9409] to ARSB
Tested applicationsSuitable for: WB, IHC-P, Flow Cytmore details
Unsuitable for: ICC or IP
Species reactivityReacts with: Human
Synthetic peptide within Human ARSB aa 450-550. The exact sequence is proprietary.
- Human placenta, HepG2, Human fetal muscle and Human fetal liver lysates; Human kidney and liver tissues
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab150374 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 46, 60 kDa.|
|IHC-P||1/50 - 1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.|
|Flow Cyt||1/10 - 1/100.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
Involvement in diseaseDefects in ARSB are the cause of mucopolysaccharidosis type 6 (MPS6) [MIM:253200]; also known as Maroteaux-Lamy syndrome. MPS6 is an autosomal recessive lysosomal storage disease characterized by intracellular accumulation of dermatan sulfate. Clinical features can include abnormal growth, short stature, stiff joints, skeletal malformations, corneal clouding, hepatosplenomegaly, and cardiac abnormalities. A wide variation in clinical severity is observed.
Arylsulfatase B activity is defective in multiple sulfatase deficiency (MSD) [MIM:272200]. MSD is a disorder characterized by decreased activity of all known sulfatases. MSD is due to defects in SUMF1 resulting in the lack of post-translational modification of a highly conserved cysteine into 3-oxoalanine. It combines features of individual sulfatase deficiencies such as metachromatic leukodystrophy, mucopolysaccharidosis, chondrodysplasia punctata, hydrocephalus, ichthyosis, neurologic deterioration and developmental delay.
Sequence similaritiesBelongs to the sulfatase family.
modificationsThe conversion to 3-oxoalanine (also known as C-formylglycine, FGly), of a serine or cysteine residue in prokaryotes and of a cysteine residue in eukaryotes, is critical for catalytic activity. This post-translational modification is severely defective in multiple sulfatase deficiency (MSD).
- Information by UniProt
- Arsb antibody
- ARSB_HUMAN antibody
- Arylsulfatase B antibody
All lanes : Anti-ARSB antibody [EPR9409] (ab150374) at 1/1000 dilution
Lane 1 : Human placenta lysates
Lane 2 : HepG2 lysates
Lane 3 : Human fetal muscle lysates
Lane 4 : Human fetal liver lysates
Lysates/proteins at 10 µg per lane.
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 46, 60 kDa
Immunohistochemical analysis of paraffin embedded Human kidney tissue labeling ARSB with ab150374 at a 1/50 dilution.
Immunohistochemical analysis of paraffin embedded Human liver tissue labeling ARSB with ab150374 at a 1/50 dilution.